Sobi Moves Forward with NASP After Complete Response from FDA on Manufacturing Data
Sobi® (STO SOBI) has just announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its Biologics License Application (BLA) for NASP, which is a combination treatment of nanoencapsulated sirolimus and pegadricase aimed at helping adults suffering from uncontrolled gout. This response from the FDA signifies that while the application is not yet approved, it highlights specific additional data requirements that Sobi needs to address before moving forward.
No significant concerns regarding the clinical safety and efficacy of NASP have been raised by the FDA, which is encouraging. However, the CRL emphasized the need for further details related primarily to the chemistry, manufacturing, and control (CMC) aspects of the drug, as well as improvements in contract manufacturing facilities. Sobi is expected to take proactive measures to engage with the FDA directly to discuss the feedback and clarify the next steps required for a successful resubmission of their BLA.
"We remain deeply committed to NASP and its potential to address the pressing unmet needs of patients with uncontrolled gout," explained Lydia Abad-Franch, M.D., M.B.A., Chief Medical Officer at Sobi. "The clinical data we have gathered supports significant reductions in serum uric acid levels among patients who struggle with this debilitating condition. The FDA’s feedback illustrates a clear path moving forward, and we look forward to collaborating closely with them toward getting NASP approved for patients in need."
Uncontrolled gout is a prevalent and painful ailment affecting over 12 million individuals in the United States alone. Gout arises when uric acid levels in the body exceed normal thresholds, leading to painful flare-ups that can cause intense discomfort and long-term joint damage. Current treatment methods sometimes fall short for approximately 200,000 people who suffer from the most severe forms of the condition. These patients continue to experience persistent and crippling symptoms, even while on traditional oral urate-lowering therapies.
NASP is an innovative investigational treatment that aims to tackle high serum uric acid (sUA) levels, thereby alleviating the deposition of harmful urate in tissues. If left unchecked, these deposits can lead to increasing rates of irreversible joint damage, along with associated health complications affecting the heart, kidney function, and overall quality of life. Administered every four weeks, NASP combines two elements in a single infusion therapy: a tolerogenic nanoencapsulated formulation of sirolimus to help mitigate anti-drug antibody formation and pegadricase to actively lower serum uric acid levels.
Founded with a mission to harness breakthrough innovations, Sobi is a leading global biopharmaceutical company dedicated to enhancing the lives of those with rare diseases. With a workforce of around 2,000 employees spread across multiple regions including Europe, North America, the Middle East, Asia, and Australia, Sobi generated revenues of SEK 28 billion in 2025. The company’s stock is publicly traded on Nasdaq Stockholm under the symbol STOSOBI. For further information regarding Sobi and its intriguing pharmaceutical endeavors, visit their website at sobi.com or their LinkedIn profile.
As Sobi prepares for the upcoming meeting with the FDA, the company aims to solidify its manufacturing processes and ensure compliance with regulatory guidelines. This careful approach will be integral in paving the way for NASP to reach the market and ultimately provide relief to countless patients enduring the challenges of uncontrolled gout. With ongoing discussions and a commitment to excellence in product development, Sobi's dedication to addressing the health needs of patients remains firm.
No significant concerns regarding the clinical safety and efficacy of NASP have been raised by the FDA, which is encouraging. However, the CRL emphasized the need for further details related primarily to the chemistry, manufacturing, and control (CMC) aspects of the drug, as well as improvements in contract manufacturing facilities. Sobi is expected to take proactive measures to engage with the FDA directly to discuss the feedback and clarify the next steps required for a successful resubmission of their BLA.
"We remain deeply committed to NASP and its potential to address the pressing unmet needs of patients with uncontrolled gout," explained Lydia Abad-Franch, M.D., M.B.A., Chief Medical Officer at Sobi. "The clinical data we have gathered supports significant reductions in serum uric acid levels among patients who struggle with this debilitating condition. The FDA’s feedback illustrates a clear path moving forward, and we look forward to collaborating closely with them toward getting NASP approved for patients in need."
Uncontrolled gout is a prevalent and painful ailment affecting over 12 million individuals in the United States alone. Gout arises when uric acid levels in the body exceed normal thresholds, leading to painful flare-ups that can cause intense discomfort and long-term joint damage. Current treatment methods sometimes fall short for approximately 200,000 people who suffer from the most severe forms of the condition. These patients continue to experience persistent and crippling symptoms, even while on traditional oral urate-lowering therapies.
NASP is an innovative investigational treatment that aims to tackle high serum uric acid (sUA) levels, thereby alleviating the deposition of harmful urate in tissues. If left unchecked, these deposits can lead to increasing rates of irreversible joint damage, along with associated health complications affecting the heart, kidney function, and overall quality of life. Administered every four weeks, NASP combines two elements in a single infusion therapy: a tolerogenic nanoencapsulated formulation of sirolimus to help mitigate anti-drug antibody formation and pegadricase to actively lower serum uric acid levels.
Founded with a mission to harness breakthrough innovations, Sobi is a leading global biopharmaceutical company dedicated to enhancing the lives of those with rare diseases. With a workforce of around 2,000 employees spread across multiple regions including Europe, North America, the Middle East, Asia, and Australia, Sobi generated revenues of SEK 28 billion in 2025. The company’s stock is publicly traded on Nasdaq Stockholm under the symbol STOSOBI. For further information regarding Sobi and its intriguing pharmaceutical endeavors, visit their website at sobi.com or their LinkedIn profile.
As Sobi prepares for the upcoming meeting with the FDA, the company aims to solidify its manufacturing processes and ensure compliance with regulatory guidelines. This careful approach will be integral in paving the way for NASP to reach the market and ultimately provide relief to countless patients enduring the challenges of uncontrolled gout. With ongoing discussions and a commitment to excellence in product development, Sobi's dedication to addressing the health needs of patients remains firm.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.